Founded in 2021, Phagos is ushering in a new era in the fight against bacterial disease with bacteriophages, a powerful alternative to antibiotics. Thanks to an unprecedented regulatory breakthrough and a discovery platform combining microbiology […]
A pioneering research network to unlock the link between gut, immune and brain health has taken its first steps at a launch event on September 22 in Southampton. Researchers and stakeholders from across the UK […]
Recent studies suggest that the steady rise in life expectancy observed over the past 200 years has now stagnated. Data indicate that a limit has been reached, and that medical and healthcare advances no longer […]
Eight years ago, 87 obese adolescents took part in a groundbreaking study to see whether fecal transfer (taking ‘good’ gut bacteria from healthy donors and giving them in capsule form to people with a less […]
A new genome-wide study uncovers evidence of the first three-way relationships between human genetic variation, variation in the fungal component of the human microbiome — known as the mycobiome — and risk of developing chronic […]
Resbiotic Nutrition, Inc., a physician-scientist founded health and wellness company, today announced it has raised a total of $14.5 million, including a recently concluded $8 million Series A round supported by major shareholders Sororibus Capital and Biostack […]
A key group of beneficial gut microbes has been found to co-evolve alongside their animal hosts, opening the door to new targeted probiotic and dietary interventions for both animals and humans. In a study published […]
When scientists discovered how bacteria protect themselves against viral invaders, called phages, in the early 2000s, little did they know they’d stumbled upon a revolutionary tool researchers could use to edit the DNA of living […]
Persephone Biosciences, a pioneering biotech company focused on unlocking the potential of the microbiome to impact human health, today announced the launch of its first consumer product: a daily synergistic synbiotic for infants and toddlers. […]
Following the closure of Bacthera’s CDMO activities, Lallemand has acquired a broad range of state-of-the-art equipment to produce drug substances and drug products in anaerobic conditions, reinforcing its GMP Pharma production capabilities for next-generation strains. […]
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced the successful closing of a €55 million (US$64 million) Series B financing round. The round was led by […]